Peoples Bank KS Buys 660 Shares of Becton, Dickinson and Company $BDX

Peoples Bank KS boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 120.0% during the second quarter, Holdings Channel reports. The fund owned 1,210 shares of the medical instruments supplier’s stock after acquiring an additional 660 shares during the period. Peoples Bank KS’s holdings in Becton, Dickinson and Company were worth $208,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Northcape Wealth Management LLC grew its holdings in Becton, Dickinson and Company by 0.5% during the 1st quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier’s stock worth $2,248,000 after acquiring an additional 51 shares during the last quarter. Alpha Omega Wealth Management LLC lifted its position in Becton, Dickinson and Company by 5.7% during the 1st quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier’s stock valued at $225,000 after purchasing an additional 53 shares during the period. Brady Family Wealth LLC lifted its position in Becton, Dickinson and Company by 1.2% during the 1st quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier’s stock valued at $989,000 after purchasing an additional 53 shares during the period. Diversified Trust Co lifted its position in Becton, Dickinson and Company by 4.7% during the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier’s stock valued at $272,000 after purchasing an additional 53 shares during the period. Finally, REAP Financial Group LLC lifted its position in Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 55 shares during the period. Institutional investors own 86.97% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on BDX shares. Argus upped their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday. Citigroup downgraded shares of Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and cut their target price for the company from $217.00 to $185.00 in a research report on Thursday, May 22nd. Barclays cut their target price on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a research report on Tuesday, June 3rd. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Four research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average target price of $213.30.

Insider Activity at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director directly owned 22,226 shares of the company’s stock, valued at $4,167,375. This trade represents a 3.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares of the company’s stock, valued at $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 2,965 shares of company stock valued at $551,536 over the last ninety days. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $188.44 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The company has a market capitalization of $54.01 billion, a P/E ratio of 33.89, a price-to-earnings-growth ratio of 1.51 and a beta of 0.27. The company’s 50 day moving average price is $187.42 and its two-hundred day moving average price is $190.65. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping the consensus estimate of $3.40 by $0.28. The firm had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the company posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 74.82%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.